ARTICLE | Company News
Boehringer Ingelheim sales and marketing update
November 17, 2014 8:00 AM UTC
Boehringer launched Ofev nintedanib in the U.S. to treat idiopathic pulmonary fibrosis (IPF). Ofev has Orphan Drug and breakthrough therapy status in the U.S. for the indication. Nintedanib is also u...